Cite
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.
MLA
Hafez, Gaye, et al. “Drugs with a Negative Impact on Cognitive Functions (Part 2): Drug Classes to Consider While Prescribing in CKD Patients.” Clinical Kidney Journal, vol. 16, no. 12, Dec. 2023, pp. 2378–92. EBSCOhost, https://doi.org/10.1093/ckj/sfad239.
APA
Hafez, G., Malyszko, J., Golenia, A., Klimkowicz-Mrowiec, A., Ferreira, A. C., Arıcı, M., Bruchfeld, A., Nitsch, D., Massy, Z. A., Pépin, M., Capasso, G., Mani, L.-Y., Liabeuf, S., & Target, , CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative. (2023). Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. Clinical Kidney Journal, 16(12), 2378–2392. https://doi.org/10.1093/ckj/sfad239
Chicago
Hafez, Gaye, Jolanta Malyszko, Aleksandra Golenia, Aleksandra Klimkowicz-Mrowiec, Ana Carina Ferreira, Mustafa Arıcı, Annette Bruchfeld, et al. 2023. “Drugs with a Negative Impact on Cognitive Functions (Part 2): Drug Classes to Consider While Prescribing in CKD Patients.” Clinical Kidney Journal 16 (12): 2378–92. doi:10.1093/ckj/sfad239.